Molecular structure of Phenylbutazone, CAS Number: 50-33-9
Phenylbutazone (CAS 50-33-9)
See product citations (1)
Application:
Phenylbutazone is an inhibitor of Cox
CAS Number:
50-33-9
Purity:
≥99%
Molecular Weight:
308.38
Molecular Formula:
C19H20N2O2
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Phenylbutazone exerts its mechanism of action by inhibiting the activity of the enzyme cyclooxygenase, specifically the COX-1 and COX-2 isoforms. This inhibition leads to a decrease in the production of prostaglandins, which are lipid compounds involved in the inflammatory response. Its mechanism of action at the molecular level involves interfering with the arachidonic acid cascade, ultimately resulting in the suppression of inflammatory mediators.
Phenylbutazone (CAS 50-33-9) References
- Anti-inflammatory drugs in the 21st century. | Rainsford, KD. 2007. Subcell Biochem. 42: 3-27. PMID: 17612044
- Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. | Takahashi, M., et al. 1990. Carcinogenesis. 11: 393-5. PMID: 2311181
- Pharmacokinetics of phenylbutazone and oxyphenabutazone in the pig. | Hvidberg, EF. and Rasmussen, F. 1975. Can J Comp Med. 39: 80-8. PMID: 234284
- Phenylbutazone (Bute, PBZ, EPZ): one drug across two species. | Worboys, M. and Toon, E. 2018. Hist Philos Life Sci. 40: 27. PMID: 29582183
- Toward of Safer Phenylbutazone Derivatives by Exploration of Toxicity Mechanism. | Borges, RS., et al. 2019. Molecules. 24: PMID: 30609687
- Phenylbutazone in the horse: a review. | Tobin, T., et al. 1986. J Vet Pharmacol Ther. 9: 1-25. PMID: 3517382
- The bioavailability of phenylbutazone in the horse. | Smith, PB., et al. 1987. Xenobiotica. 17: 435-43. PMID: 3604253
- Metabolism of phenylbutazone in rats. | Alexander, DM., et al. 1985. Xenobiotica. 15: 123-8. PMID: 4002734
- [Phenylbutazone and its analogs. Synthesis, chemical and pharmaceutical properties]. | Santoro, MI. and Ferreira, PC. 1973. Rev Farm Bioquim Univ Sao Paulo. 11: 117-41. PMID: 4612652
- Phenylbutazone and oxyphenbutazone. | . 1973. Med Lett Drugs Ther. 15: 40. PMID: 4704701
- Phenylbutazone self-poisoning treated by charcoal haemoperfusion. | Strong, JE., et al. 1979. Anaesthesia. 34: 1038-40. PMID: 539640
- Bioavailability of phenylbutazone preparations in the horse. | Rose, RJ., et al. 1982. Equine Vet J. 14: 234-7. PMID: 7106088
- Phenylbutazone in the horse. | Lees, P., et al. 1982. Vet Rec. 110: 617. PMID: 7123814
- Phenylbutazone and chromosomal damage. | Walker, S., et al. 1975. Ann Rheum Dis. 34: 409-15. PMID: 769706
- Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. | Hixson, LJ., et al. 1994. Cancer Epidemiol Biomarkers Prev. 3: 433-8. PMID: 7920212
Inhibitor of:
μ-crystallin, 9530003J23Rik, AARD, AKR1C14, AKR1C18, AKR1C19, AKR1C6, ARH1, BSA, Cox, CYP2A5, CYP2C18, Cyp2c29, Cyp2c37, Cyp2c55, Cyp2c65, Cyp2c66, Cyp2c68, Cyp2c69, CYP2C9, CYP2J11, DEXI, DHRS7C, galectin-2, Glut9, HGD, hnRNP I, LPO, PAPSS2, SerpinA1c, SerpinA3m, SLC17A4, SLC22A11, Slc22a27, UGT1A10, UGT1A3, and ZNF35.Activator of:
COL6A6, CYP2D11, CYP2W1, CYP4F11, Dtl, EG226601, EG226604, mEH, SerpinA3b, UBE2E2, and UGT2B7.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Phenylbutazone, 5 g | sc-204843 | 5 g | $31.00 |